InfoBionic has been recognized by CIOReview Magazine as the recipient of “10 Most Promising Patient Monitoring Solution Providers - 2017,” based on our proprietary methodology, reflecting its position in the industry. This profile has been developed by the CIOReview research and editorial team based on insights from an interview with Stuart Long, CEO.

InfoBionic
A Different Class in Remote Patient Monitoring

Stuart Long, CEO

Then the idea of remote cardiac telemetry was first popularized, the original Holter monitor used to record the heart’s activity was a 75-lb backpack with a reel-to-reel FM tape recorder with humongous batteries. Fast-forward to today and remote monitoring has forged a path through wireless and cellular devices to improve healthcare significantly. Transitioning from episodic office based follow-ups to continuous monitoring of patient and disease state, modern remote monitoring not only reduces clinical burden but is also the fountainhead of large data deposits which can be utilized to predict real-world outcomes. However, despite significant technological advancements in remote monitoring, most cardiac monitoring tests still compete with traditional care models when it comes to receiving timely patient and clinical information. Bridging the gap between patient and physician, InfoBionic delivers never-before-accessible control over patient data through their 3-in-1 ambulatory electrocardiograph (ECG) monitoring and arrhythmia detection system. Rather than going from one Holter monitoring device and then referring to a separate event monitor or mobile telemetry device and test, InfoBionic can accomplish this with one device, one intuitive user interface on a single platform. The company’s MoMe Kardia system is a cloud-based, automated cardiac monitoring system that delivers on-demand, true, full disclosure data, and analytics directly to physicians, eliminating the need for third-party service providers. Yet, this alone is not what sets the company apart. By allowing physicians to bill globally for 100 percent (vs. 5 percent) of the services they provide, it fully turns the reimbursement paradigm ‘right-side-up’ and gives back control to the physicians, on par with the standards they are used to inside their office or hospital’s ECG testing, stress testing and/ or echocardiography.

Unmatched beat-to-beat Insight

A one-piece device, MoMe Kardia is compact, lightweight, and also ensures complete patient compliance. Advancing the conventional model for cardiac arrhythmia detection and monitoring, InfoBionic’s solution enables practices with advantages in three main areas: data, clinical, and financial. In terms of data advantage, the company has acquired high resolution 2-channel true full disclosure which means that organizations no longer miss critical views on the onset and offset of an event as well as the ability to verify on demand reported events that clinician determine they want to be notified about. “Most service providers that claim full disclosure only offer snippets from detected events which results in greater than 99 percent data loss. However, while our device is worn, every heartbeat is detected, sent to the cloud, and every bit of high resolution data is used to make a diagnosis faster than anything in the market,” says Long. Further and in contrast to the traditional market devices where they use a single onboard algorithm to analyze the cardiac signal, we transmit the patient’s high-res 2-channel ECG directly to the cloud and use a number of artificial intelligence (A.I.) algorithms rooted in deep learning A.I. This allows a faster and much improved clinical analysis of a very high-quality ECG.

While our device is worn, every heartbeat is detected, sent to the cloud, and every bit of data is used to make a diagnosis faster than anything in the market

The advantage we have with our technology approach is that we are fully prepared for precision medicine for arrhythmia detection. This means as our data sets grow and learn we are able to personalize and select the most clinically appropriate algorithm(s) based upon each individual patient and the clinical criteria. This is something today’s solutions simply are not doing. Add to this our fortified and expansive intellectual property we will be able maintain the market leader advantage for quite some time.

The model also results in substantial reimbursement or financial advantages as it eliminates the requirement for third-party vendors. While insurance companies reimburse around $1.3 billion for remote cardiac monitoring, when third-party vendors provide their services, over 95 percent of the funds are directed toward them. Oftentimes vendors, certified centers, or independent diagnostic testing facilities (IDTF) that provide cardiac remote monitoring services are in charge of procuring and communicating final patient reports and this process takes days or weeks, creating a delay in the workflow and most importantly a potential for a delay in time to diagnosis. InfoBionic aims to make the IDTF model obsolete by offering automated software which ensures 100 percent of the reimbursement goes to the physicians or health system which provides up to 25 times more return on investment (ROI). With the MoMe Kardia monitor, medical groups or hospitals no longer have to depend on a third party provider for inventory and instead can bring the technical portion of service under their control and bill globally for the services provided using existing current procedural terminology (CPT) codes. In addition, the system offers a strong clinical advantage with 24-hour access to patient data. Physicians can easily correlate symptoms to rhythms and access the data through a user-friendly, HIPAA-compliant platform via desktop, tablet, or mobile.

In a case in point, North Suburban Cardiology Associates in Stoneham, MA was using different ambulatory monitoring strategies, the most frequent being Holter monitoring, as well as event monitoring and mobile telemetry. What piqued the medical group’s interest in InfoBionic was the 3-in-1 solution. MoMe Kardia enabled the client to select the most appropriate monitoring modality based on patient symptoms, technical awareness, insurance coverage, and patient finances.

Instead of waiting days for a report, the client has access to full disclosure data at any point in time by simply pressing a button. The same monitor was used on all patients and in case of a high index of suspicion; action could be taken immediately, instead of waiting days for a Holter or an Event Monitor to be returned. High resolution true full disclosure was also helpful in tracking the onset or termination of supraventricular tachycardia (SVT) or abnormally fast heart rhythm. Furthermore, the client also used the tool for feedback. For example, instead of providing patients with a text report of their monitor findings, with MoMe Kardia the client was able to log into the user interface and show them specific symptoms. This was engaging and reassuring for patients as they had full information about their condition. Also, if a patient had never undergone telemetry monitoring, then the cardiology center could begin with event monitoring or MCT. This remarkably simplified the workflow for the users and staff. Patients no longer had to turn to old units, and it also helped make and exclude diagnoses in a streamlined manner. With mobile telemetry, an abnormal condition was detected sooner than usual, which in turn increased efficiency while reducing the turnaround and wait time.

Resetting the Standard for Care

Under the company’s subscription as a service (SaaS) model, a client can use each device on as many patients as needed. After the first few uses, the device helps capture more revenue for the same amount of work previously done and starts paying for itself and generates quicker ROI. For maximum client benefit, InfoBionic offers a month of free trial to all clients. Focusing on a value-based system, with InfoBionic a client can enroll, get trained, and begin monitoring on the same visit itself. While most traditional service providers mail the device to a patient with an instruction video, InfoBionic trains medical staff or cardiac technicians on how to use the product as well as generate preliminary reports on the device itself.

Being a customer focused company Long firmly believes in obsessing about customers and not their competition. “My role as a CEO is to build trust, and at InfoBionic we instill the methodology of a “tacit culture™.” While tacit stands for being understood without stating it, Long has a unique acronym for it. He defines tacit as trust, accountability, creativity, innovation, and transparency. InfoBionic’s work culture is a true reflection of its value based system where productivity and accountability are set in high regard and there is an environment of mutual trust in each other, which ultimately and most importantly leads to long lasting and trusted relationships with our customers.

In the days ahead, the company is planning to expand throughout North America and subsequently internationally. According to a study by Transparency Market Research, the global cardiovascular monitoring and diagnostic devices market is expected to grow from $1.8 Bn in 2015 to $3.1 Bn by 2024. The current market of remote patient monitoring is bursting with disruption and opportunities, and InfoBionic being early to market in this innovation wave, will continue to carve a niche by improving their existing services and enabling a new standard of care. “Everyone’s heart beats the same, but when it doesn’t, we want to be there,” ends Long.

InfoBionic

InfoBionic Secures Series D Funding

Thursday, October 26, 2023

InfoBionic, a Boston, MA-based virtual telemetry company for cardiac remote patient monitoring, raised an undisclosed amount in the initial closing of its Series D funding.

The round saw participation from Security International Investments (SII), Mayo Clinic and Excel Venture Management, as well as Blue Cross Blue Shield of MA (Zaffre Investments), and Blue Cross Blue Shield of Kansasand Safeguard Scientifics.

The company intends to use the funds for the continued commercial expansion of its MoMe® ARC system for remote, wireless monitoring and diagnosis of cardiac arrhythmias.

Led by CEO Stuart Long, InfoBionic is now involved in offering and expand adoption of its recently FDA approved third-generation platform MoMe® ARC system for virtual telemetry and remote wireless monitoring and detection of cardiac arrhythmias.

The MoMe® ARC 4-in1 monitor, its 3rd Generation remote ECG monitoring device paired with their inaugural Bluetooth diagnostic 6-lead sensor is designed to aid physicians in their diagnosis of cardiac arrhythmias in patients with a demonstrated need for cardiac monitoring. Now delivering both a patch-type sensor and a wire-based system, InfoBionic has the capability to offer full disclosure, heartbeat-to-heartbeat data over the Cloud, allowing doctors 24/7 near real-time access to hospital telemetry-level data, and rapid diagnosis.

InfoBionic Enters into a Know-How Agreement with Mayo Clinic to Enhance Remote Patient Monitoring Platform

Friday, November 03, 2023

AI meets ECG to offer tailored insights for patients and clinicians, optimizing the path from hospital to home. InfoBionic CEO, Stuart Long, emphasizes their commitment to advanced remote monitoring, reducing costs, and improving patient outcomes.

BOSTON, -- InfoBionic, a digital health company providing AI-powered diagnostic remote patient monitoring solutions, today announced it has entered into an agreement with Mayo Clinic to incorporate its extensive know-how in cardiac patient monitoring, AI-ECG, and virtual telemetry to optimize and build upon its existing monitoring platform.

The collaboration aims to enhance InfoBionic's current proprietary AI algorithms and analytics capabilities to provide more personalized and predictive insights to both patients and clinicians. In addition, the agreement will help augment current development efforts in virtual cardiac telemetry to enable a seamless cardiac monitoring continuum of care from hospital to home.

"This agreement represents our enduring commitment to delivering the most advanced remote monitoring solutions available and continuing our history of industry-leading quality in remote ECG monitoring for caregivers and their patients," says Stuart Long, CEO of InfoBionic.

Healthcare teams can leverage advanced cardiac monitoring analytics and AI-powered insights to deliver improvements in care, like earlier discharges from the inpatient setting, lower readmissions, reduced costs and clinical burden associated with cardiac monitoring, optimized virtual cardiac care, and enhanced healthcare equity.

"Our reputation of integrating existing clinical workflows with more sophisticated arrhythmia analysis will gain greater momentum as we bring our new vision for virtual telemetry to fruition. This collaboration from day one has been instrumental in enabling us to drive the best possible care and outcomes for patients, wherever they are in their journey," says Long.

InfoBionic Rebrands Company Name to ‘InfoBionic.Ai’, Reinforcing Focus on AI-Enabled ECG

Friday, April 12, 2024

BOSTON --InfoBionic.Ai, a digital health company providing AI-powered diagnostic remote patient monitoring solutions, today announced that it has evolved its company name from ‘InfoBionic’ to ‘InfoBionic.Ai,’ signifying its continued commitment to leveraging artificial intelligence in virtual cardiac care.

InfoBionic has always been dedicated to remaining at the cutting edge of patient care. Since the organization’s first FDA approval in 2015, AI and machine learning have been an integral part of InfoBionic’s remote cardiac telemetry offering. InfoBionic’s use of AI goes beyond workflow optimization and into the clinical realm, embracing a future where AI-powered analysis can unlock many more of the heart’s hidden secrets. Now, the organization’s name will match its identity and its product suite: ‘InfoBionic.Ai’.

"We are proud to announce our natural evolution as an organization to ‘InfoBionic.Ai’. In reality, this name change is just formalizing what we have already become,” says Stuart Long, CEO of InfoBionic.Ai. “Our commitment to evolving remote cardiac telemetry monitoring through existing and novel AI-enabled ECG remains steadfast and unwavering. This transformation signifies our dedication to pioneering solutions that redefine the future of healthcare, as we empower providers with actionable insights and enable them to ultimately improve patient outcomes.”

Set apart from legacy approaches in one of the most critical areas of diagnostic monitoring, InfoBionic.Ai harnesses the latest biosensor technology and cloud-based AI analysis to provide the only FDA approved AI-enabled 6-lead diagnostic arrhythmia detection system with an industry-leading hospital-grade near real-time view of the heart. The organization's MoMe® ARC platform continues to push the boundaries in cardiac monitoring and accelerate the shift to truly personalized and preventative cardiac care. InfoBionic.Ai is focused on coupling advanced technology with deep clinical knowledge—a commitment which is evidenced by its collaboration with Mayo Clinic.

As for what’s next, Stuart suggests the full potential of the technology is just beginning to unfold. “The MoMe® ARC has proven that proactive cardiac care can be extended to every patient who requires it, and that AI is a key ingredient in making detecting and treating latent cardiac disease much sooner than ever before a reality for today’s busy clinicians,” he says. “But there is still so much to be done, and we have only just scratched the surface of what AI-enabled ECG will mean for the entire industry. At InfoBionic.Ai, we will continue to lead the way.”

10 Most Promising Patient Monitoring Solution Providers - 2017

Company
InfoBionic

Management
Stuart Long, CEO

Description
A digital health company that provides never-before-accessible control over patient data through their 3-in-1 ambulatory remote cardiac monitoring solution with the only SaaS cloud based true high resolution 2-channel full disclosure cardiac ECG acquisition

InfoBionic A Different Class in Remote Patient Monitoring